Ingrasciotta, Ylenia http://orcid.org/0000-0001-9038-6573
Jin, Yinzhu
Foti, Saveria S.
Landon, Joan E.
Tari, Michele
Mattace-Raso, Francesco
Kim, Seoyoung C.
Trifirò, Gianluca
Funding for this research was provided by:
Division of Pharmacoepidemiology and Pharmacoeconomics at the Brigham and Women’s Hospital
Article History
Received: 28 September 2022
Revised: 7 December 2022
Accepted: 8 December 2022
First Online: 19 December 2022
Declarations
:
: The protocol for this study using Optum data received ethics approval from the Institutional Review Board of Brigham and Women’s Hospital (Boston, Massachusetts).
: The manuscript does not contain clinical studies or patient data. For this type of study, formal consent is not required.
: Ylenia Ingrasciotta is the CEO of the academic spin-off “INSPIRE srl” of the University of Messina, which has received funding for conducting observational studies from contract research organizations (RTI Health Solutions, Pharmo Institute N.V.) and from pharmaceutical Companies (Chiesi Italia, Kyowa Kirin s.r.l., Daiichi Sankyo Italia S.p.A.). Gianluca Trifirò has served on advisory boards/seminars funded by SANOFI, Eli Lilly, AstraZeneca, Abbvie, Servier, Mylan, Gilead, and Amgen; he was the scientific director of a II level Master on pharmacovigilance, pharmacoepidemiology, and real-world evidence, which has received non-conditional contributions from various pharmaceutical companies; he coordinates a pharmacoepidemiology team at the University of Messina, which has received funding for conducting observational studies from various pharmaceutical companies (Boehringer Ingelheim, Daiichi Sankyo, PTC Pharmaceuticals). He is also chief of the academic spin-off “INSPIRE srl,” which has received funding for conducting observational studies from contract research organizations (RTI Health Solutions, Pharmo Institute N.V.) from pharmaceutical Companies (Chiesi Italia, Kyowa Kirin s.r.l., Daiichi Sankyo Italia S.p.A.). Seoyoung C. Kim has received research grants to the Brigham and Women’s Hospital from Pfizer, Roche, AbbVie, and Bristol-Myers Squibb for unrelated studies. She is also supported by NIH-K24AR078959. The other authors declare that they have no conflicts of interest.